Claritas Rx launches omnichannel CRM for patient services teams
Claritas Rx unifies hub and pharmacy workflows in one CRM, aiming to reduce access delays and improve time-to-therapy for specialty brands.
Claritas Rx has launched a Patient Services Omnichannel CRM aimed at reducing workflow fragmentation across hubs, specialty pharmacies, field teams, and internal case managers supporting rare and complex disease patients.
The product focus is less about “marketing CRM” and more about operational coordination: unifying patient-level data, partner interactions, communications, and analytics so manufacturers can spot bottlenecks earlier and standardize follow-up across stakeholders.
Table of contents
Jump to each section:
- What Claritas Rx’s patient services CRM is built to do
- Why omnichannel matters in access and time-to-therapy workflows
- How the product fits a competitive healthcare CRM landscape
- What life sciences teams should evaluate before adoption
What Claritas Rx’s patient services CRM is built to do
The CRM is positioned as a single workspace that combines configurable case management, integrated omnichannel communication, and real-time analytics. The core promise is operational visibility: one patient record, shared case history, and live status updates that can be accessed by internal teams and external partners.
A practical implication for patient services operations is reducing “handoff opacity.” When multiple parties touch prior authorization, benefits investigation, first fill, and refill support, delays often come from unclear ownership and disconnected systems. A unified case record can make it easier to track who owns the next action, what has already happened, and what is blocking progress.
Claritas Rx also frames the CRM as complementary to its Patient Watchtower product, which provides a cross-partner view of milestones and bottlenecks. Used together, the company says customers have seen a 98% response rate within 24 hours from specialty pharmacy and hub partners, which serves as a proxy metric for partner responsiveness and coordination maturity.
ContentGripWhy omnichannel matters in access and time-to-therapy workflows
“Omnichannel” here is not primarily a campaign concept. It is about coordinating patient and partner communications across channels while keeping the context attached to the case. For manufacturers, the operational outcome is fewer blind spots when patients get stuck in steps like prior authorization, benefits investigation, or refills.
The CRM also includes AI-driven orchestration features aimed at predictive risk detection and next-best-action guidance. In patient services, the value of predictive signals is straightforward: earlier identification of patients at risk of delay or drop-off can shift teams from reactive firefighting to prioritized outreach, especially when resources are limited and caseloads are high.
This aligns with broader shifts toward first-party data infrastructure and AI-supported decisioning. As manufacturers and their partners generate more journey signals across systems, the differentiator becomes whether those signals can be connected to action quickly, not just reported after the fact.
How the product fits a competitive healthcare CRM landscape
Claritas Rx operates in a specialized healthcare CRM and analytics category focused on patient-services coordination for specialty therapies. This overlaps with adjacent platforms across life sciences data, commercialization operations, and workflow tooling.
Competitively, this places it in a landscape that includes companies such as Veeva Systems, Model N, IntegriChain, and Aetion. While those vendors are often associated with broader commercial, data, and analytics footprints, Claritas Rx is emphasizing a narrower operational lane: patient services coordination across external partners with execution workflows (case management and communications) tied to patient journey analytics.
The strategic question is whether this tighter specialization helps manufacturers operationalize access and adherence improvements faster than more general-purpose life sciences platforms, especially when the hardest problems sit at the boundaries between hubs, pharmacies, and field teams.
What life sciences teams should evaluate before adoption
For teams assessing a patient-services CRM, the main evaluation criteria should go beyond feature checklists:
- Partner interoperability: How easily can specialty pharmacies, hubs, and field teams participate without creating parallel portals and duplicate data entry?
- Data governance and security model: A shared workspace implies shared access patterns, so manufacturers need clear role-based permissions and auditability.
- Signal-to-action latency: If AI identifies risk, how quickly can teams act inside the same system, and can actions be tracked back to outcomes like time-to-therapy or persistence?
- Measurement discipline: Improvements such as faster response rates are useful, but teams should define consistent metrics (first-fill conversion, time-to-therapy, refill continuity) and validate attribution across partners.
Because the category is competitively active, manufacturers should also consider whether they want a patient-services-specific operating layer, a broader suite platform, or a hybrid model where specialized tooling feeds standardized enterprise reporting.
